METHODS FOR DISRUPTING BIOFILMS

Abstract

The present invention provides methods for disrupting biofilms and/or preventing the formation of biofilms along with medical items that contain a coating or covering made of compositions for achieving such disruption or prevention. In particular, the compositions of the present invention provide random-sequence peptide mixtures for use in disrupting bacterial biofilms; the random-sequence peptides having hydrophobic and/or cationic amino acids, wherein the ratio of the total hydrophobic and cationic amino acids in the mixture is predefined.

Claims

1. An item configured to prevent biofilm formation, disrupt biofilm and/or prevent microbial contamination, wherein the item includes a coating or covering of a composition comprising a mixture of a plurality of random-sequence peptides, wherein the peptides have an identical number of amino acid residues and a length of 10 to 40 amino acid residues, wherein the mixture of peptides consists of one or more species of hydrophobic amino acids in an L- or D-configuration and one or more species of cationic amino acids in an L- or D-configuration, wherein the ratio in the mixture of the total hydrophobic and cationic amino acids is about 3:1 to 1:3, and wherein the mixture of the plurality of random-sequence peptides contains 2.sup.10 up to millions of sequences.

2. The item of claim 1, wherein the biofilm to be prevented or disrupted or the microbial contamination to be prevented is due to unicellular organisms selected from the group consisting of bacteria, fungi, and archaea.

3. The item of claim 2, wherein the bacteria are selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Bacillus cereus, Streptococcus mutans, E. coli, Listeria, Salmonella, Klebsiella, Enterococcus, and Pseudomonas aeruginosa.

4. The item of claim 2, wherein the bacteria are antibiotic-resistant bacteria.

5. The item of claim 1, wherein the hydrophobic amino acid is selected from the group consisting of phenylalanine, leucine, tryptophan, and combinations thereof, and wherein the cationic amino acid is lysine.

6. The item of claim 5, wherein the mixture consists of phenylalanine and lysine, or leucine and lysine, or tryptophan and lysine.

7. The item of claim 6, wherein the mixture consists of leucine and lysine and the ratio of leucine and lysine in the mixture is about 1:1 to 1:3.

8. The item of claim 1, wherein the peptides have a length of 15 to 25 amino acids.

9. The item of claim 1, wherein the composition is coated by immobilizing the peptides to the surface of the item.

10. The item of claim 1 selected from the group consisting of a medical device, a food or drink packaging, a food or drink container, food, food or drink processing equipment, food or drink preparation equipment, and water systems or any part thereof.

11. A method for preventing biofilm formation, disrupting a biofilm and/or preventing microbial contamination comprising applying to a surface of an item a composition comprising a mixture of a plurality of random-sequence peptides, wherein the peptides have an identical number of amino acid residues and a length of 10 to 40 amino acid residues, wherein the mixture of peptides consists of one or more species of hydrophobic amino acids in an L- or D-configuration and one or more species of cationic amino acids in an L- or D-configuration, wherein the ratio in the mixture of the total hydrophobic and cationic amino acids is about 3:1 to 1:3, and wherein the mixture of the plurality of random-sequence peptides contains 2.sup.10 up to millions of sequences.

12. The method of claim 11, wherein the biofilm to be prevented or disrupted or the microbial contamination to be prevented is due to unicellular organisms selected from the group consisting of bacteria, fungi, and archaea.

13. The method of claim 12, wherein the bacteria are selected from the group consisting of Staphylococcus aureus, Staphylococcus epidermidis, Bacillus subtilis, Bacillus cereus, Streptococcus mutans, E coli, Listeria, Salmonella, Klebsiella, Enterococcus, and Pseudomonas aeruginosa.

14. The method according to claim 12, wherein the bacteria are antibiotic-resistant bacteria.

15. The method according to claim 11, wherein the hydrophobic amino acid is selected from the group consisting of phenylalanine, leucine, tryptophan, and combinations thereof, and wherein the cationic amino acid is lysine.

16. The method of claim 15, wherein the mixture consists of phenylalanine and lysine, or leucine and lysine, or tryptophan and lysine.

17. The method of claim 16, wherein the mixture consists of leucine and lysine and the ratio of leucine and lysine in the mixture is about 1:1 to 1:3.

18. The method of claim 11, wherein applying the composition comprises applying the composition as a coating or covering of the item or otherwise immobilizing the peptides to the item's surface.

19. The method of claim 11, wherein the item is selected from the group consisting of a medical device, a food or drink packaging, a food or drink container, and water systems or any part thereof.

20. The method of claim 11 useful for food or drink processing and/or food or drink preparation.

Description

BRIEF DESCRIPTION OF THE FIGURES

[0047] FIG. 1 shows the effect of random-sequence peptide mixtures on the growth of methicillin-resistant Staphylococcus aureus (MRSA). Clinically isolated strain of MRSA was treated with random sequence 20-mer phenylalanine-lysine peptide mixtures (homochiral .sup.LF.sup.LK or heterochiral .sup.LF.sup.DK). Growth-inhibitory activities were measured after incubation of 6 hr or 24 hr.

[0048] FIG. 2 shows the effect of random sequence peptide mixtures on MRSA biofilm degradation. Random sequence 20-mer phenylalanine-lysine peptide mixtures (homochiral .sup.LF.sup.LK or heterochiral .sup.LF.sup.DK) or leucine-lysine peptide mixture (LK) were examined for their effect on MRSA biofilm biomass degradation by crystal violet staining. Degradation was compared to the antibiotic Daptomycin.

[0049] FIG. 3 shows bacterial cell viability in MRSA biofilm after treatment with phenylalanine-lysine random-sequence peptide mixture (Homochiral .sup.LF.sup.LK or heterochiral .sup.LF.sup.DK) at a concentration of 100 μg/mL.

[0050] FIG. 4 shows bacterial cell counting in MRSA biofilm after treatment with the random-sequence peptide mixtures (homochiral .sup.LF.sup.LK or heterochiral .sup.LF.sup.DK). Daptomycin was used as a positive control.

[0051] FIGS. 5A, 5B and 5C are scanning electron micrographs showing the effect of random-sequence peptide mixtures (homochiral .sup.LF.sup.LK or heterochiral .sup.LF.sup.DK) on mature MRSA biofilm. A mature MRSA biofilm grown on glass disks was treated for 24 hrs with 100 μg/mL .sup.LF.sup.LK (FIG. 5B) or with .sup.LF.sup.DK (FIG. 5C). As a control, non-treated mature MRSA biofilm is shown (FIG. 5A).

[0052] FIGS. 6A and 6B show the effect of homochiral or heterochiral mixtures of random-sequence peptides consisting of tryptophan and lysine (WK, W.sup.DK, .sup.DWK, and .sup.DW.sup.DK) on Bacillus subtilis biofilm formation. Lactobacillus-MRS (LMRS) and B. subtilis 3610 not treated with the peptide mixtures were use as control.

[0053] FIGS. 7A, 7B and 7C are representative confocal microscopy images of MRSA cells treated with labeled random-sequence peptide mixtures. Fluorescently labeled random peptide mixture (F1′-.sup.LF.sup.LK or F1′-.sup.LF.sup.DK) were incubated for 1 hr with MRSA cells and then photographed using confocal microscopy. FIG. 7A shows MRSA cells, not treated with the peptides. FIGS. 7B and 7C show MRSA cells treated with (F1′-.sup.LF.sup.LK or F1′-.sup.LF.sup.DK), respectively.

[0054] FIG. 8 shows the hemolytic activity of increasing concentrations of .sup.LF.sup.LK and .sup.LF.sup.DK towards human red blood cells.

[0055] FIG. 9 shows the viability of Caco-2 cells (a human intestinal epithelial cell line) in the presence of increasing concentrations of .sup.LF.sup.LK, .sup.LF.sup.DK, and leucine lysine (.sup.LL.sup.LK).

DETAILED DESCRIPTION OF THE INVENTION

[0056] The present invention provides pharmaceutical compositions comprising random-sequence synthetic peptide mixtures for use in treating or preventing biofilm-associated infections and/or for use in disrupting biofilm and/or for use in killing bacteria embedded in a biofilm and/or for use in preventing formation of biofilm, in a subject in need of such treatment. The present invention further provides random-sequence synthetic peptide mixtures for use in preventing biofilm formation on a surface of medical devices, on food processing surfaces, or on commercial and industrial water systems. The mixture comprises random sequence peptides of 3 to 50 amino acid residues in length, wherein the peptides comprise hydrophobic and/or cationic amino acids, and wherein the ratio in the mixture of the total hydrophobic to cationic amino acids is highly controlled and pre-defined.

[0057] Random-sequence peptide mixtures are significantly advantageous compared to anti-biofilm specific peptide sequences for two reasons: (1) the synthesis of random-sequence peptide mixtures is easy and cost-effective relative to the synthesis of specific peptide sequences; and (2) the mixtures contain many peptides with different amino acid sequences, and as such can be considered to be a cocktail of anti-biofilm agents which reduce or even eliminate the risks of acquired antibiotic resistance in bacteria.

[0058] Advantageously, it is now disclosed that mixtures of synthetic random sequence peptides comprising hydrophobic and cationic amino acids are highly efficient in preventing biofilm formation, in eradicating an existing or mature biofilm, and in killing bacteria embedded or associated with biofilms. The present invention teaches that specific amino acid sequences of antimicrobial peptides are not essential for preventing biofilm formation, for eradicating an existing biofilm, and for killing bacteria associated with biofilm.

[0059] The inventors of the present invention showed that mixtures of random sequence peptides of hydrophobic amino acids and cationic amino acids, e.g., phenylalanine-lysine, tryptophan-lysine, and leucine-lysine, showed high anti-biofilm activity. However, higher anti-biofilm activity was observed with peptide mixtures of hydrophobic aromatic amino acids and cationic amino acids, e.g., a phenylalanine-lysine mixture, in some experimental conditions. In addition, heterochiral mixtures of hydrophobic aromatic amino acids and cationic amino acids showed higher anti-biofilm activity than homochiral mixtures, and such heterochiral mixtures were found to be essentially non-toxic to human cells.

[0060] The term “biofilm” refers to a population of microorganisms, such as bacteria, growing on a surface, wherein the bacteria are encased in a matrix generally composed of polysaccharides, proteins and nucleic acids. In this state, bacteria are less susceptible to both phagocytes and antibiotics. The term “biofilm” is further intended to include biological films that develop and persist at interfaces in aqueous environments.

[0061] The terms “disrupting biofilm” and “eradicating biofilm” are used herein interchangeably and are defined as the ability of the mixtures as defined in the present invention to degrade an existing or mature biofilm and/or to inhibit, prevent, or reduce the formation of a biofilm in vitro as well as in vivo and/or to kill microorganisms embedded or associated with biofilms.

[0062] The terms “preventing biofilm formation” or “reducing biofilm formation” are used herein interchangeably and refer to the ability of the mixtures disclosed herein to avert or reduce the formation of a biofilm by microorganisms. According to some embodiments, preventing biofilm formation means inhibiting bacterial attachment to a surface. Additionally, or alternatively, preventing biofilm formation means killing the biofilm-forming bacteria.

[0063] The term “mixture” as used herein refers to at least two different random-sequence peptides as discloses herein, preferably to a plurality of random-sequence peptides. According to the invention, the mixture of random-sequence peptides comprises or consists of cationic amino acids and hydrophobic amino acids. The mixture can be mixed with another anti-microbial agent.

[0064] The term “random-sequence peptide” as used herein refers to a peptide, the amino acid sequence of which is different from the amino acid sequence of at least one peptide in the mixture. According to some embodiments, the mixture can have up to 2.sup.n amino acid sequences, wherein n defines the number of coupling steps in the peptide synthesis, if one species of a cationic amino acid residue and one species of a hydrophobic amino acid residue are present both in L-configuration or D-configuration. According to further embodiments, the mixture can have up to 4.sup.n amino acid sequences, wherein n defines the number of coupling steps in the peptide synthesis, if one species of a cationic amino acid residue and one species of a hydrophobic amino acid residue are present in L-configuration and D-configuration. Thus, the number of random-sequence peptides in a mixture is dictated by the length of the peptides synthesized, the various species of amino acids, and the configuration of the amino acids.

[0065] According to the invention, the random-sequence peptides comprise or consist of hydrophobic and/or cationic amino acids. According to some embodiments of the invention, one or more peptides in the mixture, preferably 10% or less, such as less than 1% of the peptides in the mixture, comprise or consist of hydrophobic amino acids but are devoid of cationic amino acids, one or more peptides in the mixture, preferably about 10% or less, such as less than 1% of the peptides in the mixture, comprise or consist of cationic amino acids but are devoid of hydrophobic amino acids, and at least about 80% of the peptides in the mixture, alternatively at least about 90%, 95%, or preferably at least about 99% of the peptides in the mixture comprise or consist of a combination of cationic and hydrophobic amino acids. According to a certain embodiment, the peptides of the mixture comprise or consist of a combination of hydrophobic and cationic amino acid residues.

[0066] The term a “cationic amino acid” refers to a positively charged amino acid, also known as a basic amino acid.

[0067] The term “ratio” as applied to the amino acids within a mixture refers to the ratio between different classes of amino acids which constitute the peptides present in the mixture. For example, “a ratio in the mixture of the total hydrophobic and cationic amino acids” refers to the number of all hydrophobic amino acids present in or constitute the peptides of the mixture relative to the number of all cationic amino acids present in or constitute the peptides of the mixture.

[0068] The term “stereoisomeric forms” refers to the L- or D-configuration of amino acids.

[0069] Unless otherwise mentioned or indicated, the amino acids are in L configuration.

[0070] The term “homochiral” as used herein refers to amino acids having the same configuration (i.e., L-configuration or D-configuration).

[0071] The term “heterochiral” as used herein refers to amino acids having different configurations, i.e., one is in the L-configuration and the other is in the D-configuration.

[0072] The term “heterochiral mixture” as used herein refers to a mixture comprising random-sequence peptides; at least one of the peptides consists of amino acids in the L-configuration and amino acids in the D-configuration. Preferably, a heterochiral mixture comprises a plurality of peptides consisting of amino acids in the L-configuration and amino acids in the D-amino configuration.

[0073] The term “homochiral mixture” as used herein refers to a mixture comprising random-sequence peptides, wherein all the peptides consist of amino acids in the L-configuration or in the D-configuration.

[0074] The singular forms “a”, “an” and “the” include corresponding plural references unless the context clearly dictates otherwise.

[0075] As used herein, the term “about” means plus or minus 10% of the numerical value indicated.

[0076] According to some embodiments, disrupting the biofilm is characterized by reducing the biofilm biomass by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% compared to a non-treated biofilm. Each possibility represents a separate embodiment of the invention.

[0077] According to some embodiments, the biofilm formation is reduced by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% compared to a non-treated site. Each possibility represents a separate embodiment of the invention.

[0078] According to some embodiments, disrupting the biofilm is characterized by killing at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the bacterial population in the biofilm.

[0079] Cationic amino acids as used herein are selected from cationic or positively charged amino acids known in the art. Positively charged amino acids include, but are not limited to, lysine, arginine, and histidine. Hydrophobic amino acids as used herein are selected from hydrophobic amino acids known in the art. Hydrophobic amino acids include, but are not limited to, phenylalanine, tryptophan, leucine, isoleucine, glycine, alanine, and valine. According to some embodiments, the hydrophobic amino acid is a hydrophobic aromatic amino acid. According to certain embodiments, the hydrophobic aromatic amino acid is phenylalanine or tryptophan. The peptides of the present invention comprise L-amino acids, D-amino acids, or a combination thereof. The amino acids may also be selected from non-protein amino acids, such as, for example, ornithine. The amino acids of the invention can be non-natural amino acids such as, for example, n-methylated amino acids, γ-amino acids, and ring-substituted phenylalanine.

[0080] The peptides of the present invention can further comprise additional amino acid residues, such as polar or uncharged amino acid residues, for example, asparagine and/or serine, as long as the ratio between the total r cationic amino acid residues and the total hydrophobic amino acid residues in the mixture is maintained between about 10:1 to 1:10, alternatively about 5:1 to 1:5, alternatively about 3:1 to 1:3, and preferably about 1:1.

[0081] According to some embodiments, the random-sequence peptides in the mixture comprise or consist of hydrophobic amino acid residues, cationic amino acid residues, or a combination thereof. According to additional embodiments, the random-sequence peptides comprise or consist of one species of a hydrophobic amino acid residue and one species of cationic amino acid residue. According to exemplary embodiments, the random-sequence peptide mixture consists of phenylalanine and lysine, tryptophan and lysine, or leucine and lysine. According to a certain embodiment, the random-sequence peptide mixture consists of phenylalanine and lysine, or tryptophan and lysine.

[0082] The random-sequence peptide mixtures of the present invention can be synthesized by a solid phase peptide synthesis method as described herein below. The random-sequence peptide mixtures can also be synthesized by other solid phase peptide synthesis methods, such as the solid-phase mix-and-split combinatorial synthesis method, as known in the art.

Pharmaceutical Compositions

[0083] The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of random-sequence synthetic peptide mixtures of the invention and a pharmaceutically acceptable carrier or diluent, for use in disrupting biofilm or for treating or preventing biofilm-associated infection in a subject.

[0084] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one pharmaceutically active ingredient.

[0085] The pharmaceutical compositions of the present invention comprise a pharmaceutically acceptable carrier. The term “carrier” refers to a diluent or vehicle with which the therapeutic compound is administered. Carrier(s) are “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. Such pharmaceutical carriers can be sterile liquids, such as water; oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like; polyethylene glycols; glycerin; propylene glycol; or other synthetic solvents. For injectable solutions, water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers for injectable solutions.

[0086] The pharmaceutical composition can further comprise a surfactant. According to some embodiments, the surfactant is a nonionic surfactant. Nonionic surfactants include, but are not limited to, sorbitan fatty acid esters, polyoxysorbitan fatty acid esters, polyoxyalkylene higher alcohol ethers, and polyoxyalkylene higher alcohol esters. Thus, nonionic surfactants include polyoxyethylene sorbitol esters such as polysorbate 80 (TWEEN® 80), polysorbate 60 (TWEEN® 60) and polysorbate 20 (TWEEN® 20), Tyloxapol; polyoxyethylene isooctylphenyl ethers such as Triton X-100, polyoxyethylene nonylphenyl ethers such as NP-40, polyoxyethylene dodecyl ethers such as Brij 58, octyl glucoside, and alkyl maltoside such as n-dodecyl-beta-D-maltoside; Poloxamer 4070; Poloxamer 188; and polyoxyl 40 stearate. Each possibility is a separate embodiment of the invention. TWEEN® and Poloxamer surfactants are preferred because they are FDA approved for human use.

[0087] The pharmaceutical compositions of the present invention can be formulated as a liquid. The liquid composition can be stored as is or can be stored in a frozen state, or in a dried form for later reconstitution into a liquid form or other form suitable for administration to a subject.

[0088] The compositions may be suitably formulated for subcutaneous, intramuscular, intraperitoneal or intravenous administration and comprise sterile aqueous solutions, which are preferably isotonic. Such formulations are typically prepared by dissolving solid active ingredients in water containing physiologically compatible substances such as sodium chloride, glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. These may be prepared in unit or multi-dose containers, for example, sealed ampoules or vials.

[0089] The compositions may incorporate a stabilizer, such as for example polyethylene glycol, proteins, saccharides (for example, trehalose), amino acids, inorganic acids and admixtures thereof. Stabilizers are used in aqueous solutions at the appropriate concentration and pH. The pH of the pharmaceutical composition of the present invention is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8.

[0090] According to some embodiments, the compositions of the invention may be formulated for oral administration in liquid solutions, emulsions, suspensions, tablets, dragees, capsules, powder, and the like. The pharmaceutically-acceptable carriers suitable for preparation of such compositions are well known in the art. Proteins or peptides that are orally administered need to be protected as to avoid digestion by the gastrointestinal system.

[0091] The mixtures of the invention can be coated with enteric coating layer(s) as to protect the peptides from digestion. Enteric coating layer(s) may be applied using standard coating techniques. The enteric coating materials may be dissolved or dispersed in organic or aqueous solvents and may include one or more of the following materials: methacrylic acid copolymers, shellac, hydroxypropylmethylcellulose phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose, carboxymethylethylcellulose, cellulose acetate phthalate or other suitable enteric coating polymer(s). The pH at which the enteric coat will dissolve can be controlled by the polymers, combination and ratio of selected polymers, and/or their side groups. For example, dissolution characteristics of the polymer film can be altered by the ratio of free carboxyl groups to ester groups. Enteric coating layers also contain pharmaceutically acceptable plasticizers such as triethyl citrate, dibutyl phthalate, triacetin, polyethylene glycols, polysorbates or other plasticizers. Additives such as dispersants, colorants, anti-adhering and anti-foaming agents may also be included.

[0092] The compositions of the invention may be formulated as controlled release preparations which may be achieved through the use of a polymer to complex or absorb the proteins of the invention. Appropriate polymers for controlled release formulations include, for example, polyester, polyamino acids, polyvinyl, pyrrolidone, poly (lactic acid), ethylene vinylacetate, ethylene vinylacetate copolymers, and cellulose derivatives such as methylcellulose. Alternatively, it is possible to entrap the proteins of the invention in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, and nanoparticles.

[0093] The compositions of the present invention can further comprise an additional therapeutic agent.

[0094] According to some embodiments, the therapeutic agent is an antibiotic agent. The antibiotic agents include, but are not limited to, β-lactams, aminoglycosides, fluoroquinolones, macrolides, novobiocin, rifampicin, oxazolidinones, fusidic acid, mupirocin, pleuromutilins, daptomycin, vancomycin, tetracyclines, sulfonamides, chloramphenicol, trimetoprim, fosfomycin, cycloserine, polymyxin, azithromycin, clarithromycin, dirithromycin, erythromycin, troleandomycin, roxithromycin, spiramycin, aztreonam, imipenem, meropenem, ertapenem, doripenem, panipenem/betamipron, biapenem, PZ-601, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, demeclocycline, doxycycline, minocycline, oxytetracycline, tetracycline, bacitracin, colistin, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and trovafloxacin.

[0095] The antibiotic agent can be one or more of the known host-defense peptides (HDPs).

[0096] According to some embodiments, the composition of the invention improves the activity of the antibiotic agent. Improving the efficacy of the antibiotic agent includes any aspect of improving or enhancing the effect of the antibiotic agent, e.g., so that the anti-biofilm effect of the antibiotic agent is increased or enhanced in any way over the effect of the antibiotic agent seen in the absence of the mixtures according to the invention. This may be seen, for example, in a stronger effect of the antibiotic agent in inhibiting growth of the bacteria, requiring less antibiotics to achieve the same effect seen in the absence of the mixtures according to the invention, or an increased effectiveness seen as increased speed or rate of action, a biofilm eradicating effect being seen in less time than in the absence of said mixtures.

[0097] According to further embodiments, the therapeutic agent is an antiviral drug or an anti-fungal drug.

Therapeutic Uses of Random Sequence Peptide Mixtures

[0098] The present invention provides uses of the pharmaceutical compositions comprising a therapeutically effective amount of random sequence peptide mixtures of the invention for disrupting biofilm in a subject in need.

[0099] According to an aspect, the present invention provides a method for treating a biofilm-associated infection in a subject comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a mixture of random-sequence peptides according to the invention and a pharmaceutically acceptable carrier.

[0100] Biofilm-forming bacteria, such as staphylococci, Staphylococcus aureus, Enterococcus faecalis, Streptococcus spp., Escherichia coli, Klebsiella pneumoniae, Acinetobacter spp., Proteus mirabilis, Pseudomonas aeruginsa and Candida spp, Staphyloccus saprophyticus, Staphyloccocus xylosus, Staphyloccocus lugdunensis, Staphyloccocus schleiferi, Stapylococcus caprae, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus saprophyticus, Staphylococcus warneri, MRSA, Enterococcus faecalis (including Vancomycin-resistant enterococcus VRE), Proprionibacterium acnes, Bacillus cereus, Bacillus subtilis, Listeria monocytogenes, Streptococcus pyrogenes, Streptococcus salivarius, or Streptococcus mutans are associated with a broad spectrum of biofilm-associated infections, particularly of nosocomial infections. The bacterial microorganisms form biofilm to be protected against the immune system. The mixtures of the inventions are useful in killing the biofilm forming bacteria as well as other bacteria that may be protected by the biofilm.

[0101] The methods of the invention are useful in treating any biofilm-associated infection. The infection can be, for example, in the oral cavity, the reproductive tract, the urinary tract, the respiratory tract, the gastrointestinal tract, the peritoneum, the middle ear, the prostate, vascular intima, the eye, including the conjunctiva or corneal tissue, in the lung tissue, heart valves, skin, scalp, nails, in wounds; or in the blood.

[0102] Typical bacterial infections associated with biofilms in humans are: wound infections, in particular wounds associated with diabetes mellitus, tonsillitis, osteomyelitis, bacterial endocarditis, sinusitis, infections of the cornea, urinary tract infection, infection of the biliary tract, infectious kidney stones, urethritis, prostatitis, catheter infections, gastrointestinal infections, Legionnaire's disease, middle-ear infections, dental plaques, gingivitis, periodontitis, cystic fibrosis, and infections of permanent indwelling devices such as joint prostheses, and heart valves.

[0103] Skin infections include, but are not limited to, cellulitis, folliculitis, impetigo, and boils.

[0104] The infection may be acute, or alternatively chronic, e.g., an infection that has persisted for at least 5 or at least 10 days, particularly at least 20 days, more particularly at least 30 days, most particularly at least 40 days.

[0105] The biofilm-associated infection can occur in any subject but some subjects will be more susceptible to infection than others. Subjects who are susceptible to these infections include, but are not limited to, subjects whose epithelial and/or endothelial barrier is weakened or compromised, subjects whose secretion-based defenses to microbial infection have been abrogated, disrupted, or weakened, and subjects who are immunocompromised, immunodeficient or immunosuppressed (i.e., a subject in whom any part of the immune response, or an immune activity is reduced or impaired, whether due to disease or clinical intervention or other treatment, or in any way).

[0106] The term “therapeutically effective amount” as used herein refers to an amount of the active agent, namely a mixture according to the invention that is sufficient to treat, alleviate, and/or inhibit one or more symptoms of a disease or disorder associated with the formation of biofilm in an individual. The therapeutically effective amount will vary depending on the active agent, formulation, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.

[0107] The dosage and route of administration used in a method of disrupting a biofilm in a subject according to the present invention depends on the specific disease/site of infection to be treated.

[0108] As used herein, the term “treating” means remedial treatment, and encompasses the terms “reducing”, “suppressing”, “ameliorating” and “inhibiting”, which have their commonly understood meaning of decreasing or arresting an infection.

[0109] The pharmaceutical composition of the invention may be administered by any suitable administration route, such as by parenteral or by oral administration route. According to some embodiments, the route of administration is via parenteral injection. According to additional embodiments, the parenteral route of administration is selected from the group consisting of subcutaneous, intramuscular, intradermal, intraperitoneal, intravenous, intraarterial, and intrathecal. The compositions of the invention can be administered locally.

[0110] The pharmaceutical composition of the present invention can be administered once a week, twice a week, three times a week for a period of at least two weeks, three weeks, four weeks, 2 months, 3 months, 4 months, 5 months, 6 months, or 12 months or any integer in between as required so as to disrupt or prevent the formation of biofilm. Each possibility represents a separate embodiment of the invention.

[0111] The dosage of random sequence peptide mixture administered can range from about 10 ng/kg to about 500 mg/kg of the subject's weight or any integer in between. According to some embodiments, the dosage of random sequence peptide mixtures administered ranges from about 20 ng/kg to about 20 mg/kg of the subject's weight. According to some embodiments, the dosage of pharmaceutical composition comprising the mixture of the invention, when administered intravenously, ranges from about 3 mg/kg to 10 mg/kg daily for 2-6 weeks.

[0112] According to some embodiments, the method of the present invention comprises a combination therapy wherein a therapeutic agent formulated in a separate composition can be administered before, simultaneously, or after the compositions of the present invention or in alternate schedule.

Other Uses of Random-Sequence Peptide Mixtures

[0113] According to an additional aspect, the present invention provides a method for preventing the formation of biofilm on a medical device, catheter or implant comprising contacting the medical device, catheter or implant with a composition comprising a mixture of random-sequence peptides according to the invention.

[0114] According to some embodiments, the medical device includes, but is not limited to, a cardiac rhythm management device (CRMD), a neurostimulator, a pulse generator, a drug pump or infusion device, a physiological monitoring device, and a textured or smooth breast implant.

[0115] Medical devices include, but are not limited to, disposable or permanent or indwelling catheters, (e.g., central venous catheters, dialysis catheters, long-term tunneled central venous catheters, short-term central venous catheters, peripherally inserted central catheters, peripheral venous catheters, pulmonary artery Swan-Ganz catheters, urinary catheters, and peritoneal catheters), long-term urinary devices, tissue bonding urinary devices, vascular grafts, vascular catheter ports, wound drain tubes, ventricular catheters, hydrocephalus shunts, heart valves, heart assist devices (e.g., left ventricular assist devices), pacemaker capsules, pulmonary ventilators, incontinence devices, penile implants, small or temporary joint replacements, urinary dilator, cannulas, elastomers, surgical instruments, dental instruments, tubings, such as intravenous tubes, breathing tubes, dental water lines, dental drain tubes, feeding tubes, fabrics, paper, adhesives (e.g., hydrogel adhesives), bandages, orthopedic implants, and any other device used in the medical field.

[0116] Medical devices also include any device which may be inserted or implanted into a human or other animal, or placed at the insertion or implantation site such as the skin near the insertion or implantation site, and which include at least one surface which is susceptible to colonization by biofilm embedded microorganisms.

[0117] The compositions comprising the mixture of the invention can be used as a sanitizing agent. Said sanitizing agent can be used, for example, before or after surgery.

[0118] The composition can be further used as a disinfectant e.g., in human organ surgery, in dental surgery, in animal surgery. For that aim, the mixtures of the invention can be prepared in a composition in the form of e.g., a spray, a fluid, a powder, a gel, or as an ingredient of a wet wipe or a disinfection sheet product. Said compositions may additionally comprise suitable carrier, additives, diluting agents and/or excipients for its respective use and form.

[0119] According to another aspect, the present invention provides an item, such as, a medical device, catheter or implant, coated with or covered by the composition of the present invention. The coating of the composition comprising the mixture of random-sequence peptides can be in some embodiments via covalent binding so that the peptides are immobilized to the surface of the item.

[0120] The surface can be made of any material. For example, it may be metal, e.g., aluminum, steel, stainless steel, chrome, titanium, iron, alloys thereof, and the like. The surface can also be plastic, for example, polyolefin (e.g., polyethylene, (Ultra-High Molecular Weight) polyethylene, polypropylene, polystyrene, poly(meth)acrylate, acrylonitrile, butadiene, ABS, acrylonitrile butadiene, etc.), polyester (e.g., polyethylene terephthalate, etc.), and polyamide (e.g., nylon), combinations thereof, and the like. Other examples include acetal copolymer, polyphenylsulfone, polysulfone, polythermide, polycarbonate, polyetheretherketone, polyvinylidene fluoride, poly(methyl methacrylate) and poly(tetrafluoroethylene). The surface can also be ceramic, porcelain, gold, and the like.

[0121] The compositions comprising a mixture of random-sequence peptides according to the invention can be used for the prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of food stuff, of food processing equipment, of food processing plants, and of water systems.

[0122] Surfaces exposed to microbial contact or contamination include in particular any part of: food or drink processing, preparation, storage or dispensing machinery or equipment, air conditioning apparatus, industrial machinery, e.g., in chemical or biotechnological processing plants, and storage tanks. Any apparatus or equipment for carrying or transporting or delivering materials is susceptible to microbial contamination. Such surfaces will include particularly pipes (which term is used broadly herein to include any conduit or line). Representative inanimate or abiotic surfaces include, but are not limited to, food processing, storage, dispensing or preparation equipment or surfaces, tanks, conveyors, floors, drains, coolers, freezers, equipment surfaces, walls, valves, belts, pipes, air conditioning conduits, cooling apparatus, food or drink dispensing lines, heat exchangers, boat hulls or any part of a boat's structure that is exposed to water, dental waterlines, oil drilling conduits, contact lenses and storage cases. Surfaces of water systems exposed to microbial contact or contamination include in particular any part of: pipes and tubes, valves, filters, reservoirs, basins, and any part in water irrigation systems.

[0123] According to some embodiments, the composition can be a cosmetic composition. For example, the cosmetic composition can be used for eliminating, reducing and/or preventing biofilm-associated bacterial growth on a human skin.

[0124] The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way, however, be construed as limiting the broad scope of the invention. One skilled in the art can readily devise many variations and modifications of the principles disclosed herein without departing from the scope of the invention.

EXAMPLES

Materials and Methods

(i) Chemicals

[0125] Fmoc-protected L/D α-amino acids with acid-labile side-chain protecting groups were purchased from Novabiochem. N-hydroxybenzotriazole (HOBt), N,N-dimethylformamide (DMF), and N,N-diisopropylethylamine (DIEA) were purchased from Sigma-Aldrich. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) was purchased from Anaspec. Dehydrated LB culture medium (244610) was obtained from BD (Franklin Lakes, N.J.). All other chemicals were purchased from Sigma Aldrich and used without purification.

(ii) Synthesis of Random-Sequence Peptide Mixtures

[0126] Random peptide mixtures were synthesized using microwave irradiation on Rink Amide resin (Substitution 0.2 mmol/gr, 25 μmol) in Alltech filter tubes. Coupling reactions were conducted with binary combinations of L/D-protected amino acids, with a freshly prepared stock solution that contained the protected amino acids in 1:1 molar ration, which was used for each coupling step. Before each coupling step, an aliquot containing 4 equiv. (100 μmol) of the amino acid mixture was activated with 4 equiv. of HBTU, 4 equiv. of HOBt, and 8 equiv. of DIEA, in DMF. After the activated amino acid solution was added to the solid-phase synthesis resin, the reaction mixture was heated to 70° C. in a MARS V multimode microwave (2 minute ramp to 70° C., 4 minute hold 70° C.) with stirring. Fmoc deprotection reactions used 20% piperidine in DMF. Reaction solutions were heated to 80° C. in the microwave (2 minute ramp to 80° C., 2 minute hold 80° C.) with stirring. After each coupling/deprotection cycle the resin was washed 3 times with DMF. Upon completion of the synthesis, the peptide mixture was cleaved from the resin by stirring the resin in a solution containing 95% trifluoroacetic acid (TFA), 2.5% water, and 2.5% triisopropylsilane for 3 hours. The peptide mixture was precipitated from the TFA solution by addition of cold ether. The precipitated peptide mixture was collected by centrifugation. Ether was removed, and the pellet was dried under a stream of nitrogen, frozen in dry ice and lyophilized.

(iii) Bacterial Growth Inhibition Assays (MIC)

[0127] Assays were performed as previously reported (Hayouka, Z. et al., J. Am Chem Soc. 2013, 135: 32). The bacteria used in these assays was methicillin resistant Staphylococcus aureus 1206 (Weisblum, B. et al., J Bacteriol, 1969, 98, 447). Antibacterial activities were determined in sterile 96-well plates (BD Falcon 353072 tissue culture plates). Bacterial cells were grown overnight at 37° C. on agar, after which a bacterial suspension of approximately 2×10.sup.6 CFU/mL in Luria Bertani (LB) growth medium was prepared. Samples (50 μL) of this suspension were added to 50 μL of medium containing the random-sequence peptide mixture in 2-fold serial dilutions for a total volume of 100 μL in each well. The plates were then incubated at 37° C. for 6 or 24 hours. Bacterial growth was determined by measuring the optical density (OD) at 650 nm (Tecan Safire plate reader). The positive control was OD without the addition of peptide mixture. The minimum inhibitory concentration (MIC) is defined as the lowest concentration at which complete inhibition of bacterial growth was observed (no increase in OD over the course of the experiment).

(iv) Biofilm Assay

[0128] Clinical isolate strain of S. aureus (1206) was used. Bacterial cells were grown overnight at 37° C. on agar, after which a bacterial suspension of approximately 2×10.sup.6 CFU/mL in LB medium was prepared. 100 μL of the bacterial suspension was then inoculated in several wells of a 96 well plate and incubated overnight at 37° C. The supernatant liquid was discarded and the wells were washed with milli-Q water three times. 100 μL of LB medium containing the random peptide mixture or antibiotic in 2-fold serial dilutions were added to the wells containing the biofilm and the plates were incubated overnight at 37° C. (in the biofilm biomass assay for daptomycin, all antibiotic/biofilm mixture at varied daptomycin concentration contained 1 mM CaCl.sub.2). The supernatant liquid was discarded. The wells were then washed with milli-Q water three times.

(v) Crystal Violet Assay for Biomass Quantification

[0129] The wells were treated with 125 μL of 0.1% crystal violet and incubated for 15 min at 37° C. Excess crystal violet was washed off thoroughly with milli-Q water three times. 125 μL of 30% acetic acid was added to each well and the solution was transferred to a new 96-well plate, and absorbance was measured at 550 nm (Tecan Safire plate reader) using 30% acetic acid in water as blank. The results were expressed as a percentage of biomass in the control biofilm, which was grown without any treatment.

(v) XTT Assay for Cell Viability within Biofilm

[0130] Cell viability in the biofilms was quantified after incubation with random-sequence mixture or antibiotic for 24 hours by an XTT assay. XTT (1 mg/mL) and phenazine methosulfate in the ratio 3:1 were freshly prepared in 1×PBS buffer. Following the washing step of the biofilm after treatment, 100 μL of this solution was added to the wells and the plates were incubated at 37° C. for 3 hours in the dark. An aliquot of 90 μL was taken and transferred to a 96-well plate and OD was measured at 490 nm (Tecan Safire plate reader) using the XTT solution as blank. The results were expressed as a percentage of cell viability relative to the control biofilm without any treatment.

Example 1

Effect of Random Sequence Peptide Mixtures on the Growth of Methicillin-Resistant Staphylococcus aureus

[0131] The ability of the random-sequence peptide mixture to inhibit the growth of planktonic MRSA cells after 6 h or 24 h was examined. As shown in FIG. 1, 20-mer random-sequence peptide mixtures of 1:1 homochiral or heterochiral phenylalanine-lysine (.sup.LF.sup.LK or .sup.LF.sup.DK) inhibited the growth of planktonic MRSA at a very low concentration. The Minimal Inhibition Concentration (MIC) was 6 μg/mL for 6 h incubation and 12 μg/mL for 24 h incubation.

Example 2

Random Sequence Peptide Mixtures Disrupt Biofilms

[0132] Biofilm biomass disruption was quantified using an assay that measures crystal violet absorbance at 550 nm to assess surface-attached biomass (O'Toole, G. A. et al., Mol Microbiol 1998, 30, 295-304). The results indicated that heterochiral mixture of 1:1 phenylalanine and lysine (.sup.LF.sup.DK) at 25 μg/mL showed stronger biofilm biomass disruption (22% of the biofilm biomass remained) compared to the homochiral (.sup.LF.sup.LK) mixture (55%). At a higher concentration (200 μg/mL), both random-sequence peptide mixtures (homochiral and heterochiral) were highly active (FIG. 2). The differences in the observed activity profile are probably due to the stability of the mixtures. The homochiral peptide mixture is probably more sensitive to protease activity than the heterochiral peptide mixture. Daptomycin, a lipopeptide antibiotic that is being used in the treatment of systemic and life-threatening infections caused by MRSA was used as a positive control in this study. Daptomycin was shown previously to disrupt biomass biofilm of MRSA. Biofilm biomass disruption was also evaluated for a mixture of 1:1 leucine and lysine. As shown in FIG. 2, lower activity was observed for the leucine-lysine mixture.

[0133] Next, XTT assay was used to quantify the cell viability of bacterial cells in the biofilm matrix after treating with the random-sequence peptides mixtures for 24 hr. The results showed that only 5% of the MRSA bacterial cells survived the treatment of the heterochiral mixture, compared to a significantly higher extent of cell survival (40%) when treated with the homochiral mixture (FIG. 3). The killing of the bacterial cell within the biofilm was further evaluated by cell counting. The biofilm biomass was sonicated and plated to measure the viability of MRSA inside the biofilm biomass after treatment. The heterochiral mixture treatment killed most of the bacterial cells within the biofilm biomass (FIG. 4).

[0134] For further characterization of the ability of the mixtures to eradicate the MRSA established biofilm, a Scanning Electron Microscopy (SEM) study was performed. A mature MRSA biofilm was grown on glass disks for 48 h, then was treated with 100 μg/mL of .sup.LF.sup.LK or .sup.LF.sup.DK for 24 h and viewed under a scanning electron microscope (FIGS. 5A, 5B and SC). As shown in the figure, .sup.LF.sup.DK was able to remove MRSA biofilms more efficiently (FIG. 5C) compared to the homochiral mixture .sup.LF.sup.LK (FIG. 5B).

Example 3

Effect of Random Sequence Peptide Mixtures of Tryptophan and Lysine on B. subtilis Forming Biofilm

[0135] The effect of random sequence peptide mixture on biofilm formation was investigated using mixtures of peptides prepared with tryptophan and lysine. The anti-biofilm effect of random-sequence peptide mixtures that contain tryptophan and lysin in 4 different stereoisomeric forms (.sup.LW.sup.LK, .sup.LW.sup.DK, .sup.DW.sup.LK, .sup.DW.sup.DK) was examined on B. subtilis 3610.

[0136] The Bacillus subtilis wild strain NCIB3610 and Bacillus subtilis that was isolated from milk were used in this study. Lactobacillus-MRS Broath (LMRS Broath) is an enriched selective medium intended for the isolation and cultivation of Lactobacillus found in clinical specimens and dairy and food products. This media was found to be very effective to grow Bacillus subtilis pellicle, a biofilm floating at the air-liquid interface. For biofilm generation, bacteria were grown to stationary phase in LMRS at 37° C. in shaking culture to around 1×10.sup.8 CFU per ml. Biofilms were generated at 30° C. in the biofilm promoting medium LMRS. As shown in FIG. 6A, a very thick biofilm was developed in the control bacteria (B. sub 3610 lane). In contrary, inhibition in the formation of biofilm (50 μg/mL) was observed in wells that were treated with WK, W.sup.DK, or .sup.DWK random peptide mixtures (FIGS. 6A and 6B). The .sup.DW.sup.DK peptide mixture exhibited lower activity, wherein biofilm formation was inhibited at 100 μg/mL (FIG. 6B). These results demonstrate that the random peptide mixtures inhibit biofilm formation of B. subtilis.

Example 4

Random-Sequence Peptide Mixtures Penetrate MRSA Cells

[0137] To study if the mixtures of the invention penetrate the bacterial cells, random sequence peptide mixtures (.sup.LF.sup.LK or .sup.LF.sup.DK) were synthesized and labeled at their N′ terminus free amino group with 5(6)-carboxyfluorescein. Confocal microscopy was used to determine their ability to penetrate MRSA bacterial cells (FIGS. 7A, 7B and 7C). After 1 h of incubation, the heterochiral and homochiral mixtures were observed in MRSA bacterial cells (FIGS. 7B and 7C, respectively). It is assumed that some of the random peptide mixtures caused damage to the bacterial membrane, and enhanced the entry of other random peptides into the bacterial cells.

Example 5

Random-Sequence Peptide Mixtures Effect on Human Cells

[0138] The random peptide mixtures (.sup.LF.sup.LK or .sup.LF.sup.DK) were examined for their red blood cell hemolysis activity as described before (Hayouka et al., J. Am. Chem. Soc., 2013, 135, 11748-11751). The heterochiral peptide mixture showed lower hemolytic activity towards human red blood cells compared to the homochiral mixture (FIG. 8).

[0139] The cytotoxicity of the random-sequence peptide mixtures was further tested on Caco-2 (European Collection of Animal cell Cultures, UK) cells. This human intestinal epithelial cell line was used between passages 30-50. Caco-2 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 2 mM L-glutamine, 1% (v/v) non-essential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% (v/v) fetal bovine serum (Sigma-Aldrich, Ireland). The cells were grown at 37° C. in a humidified atmosphere with 5% CO.sub.2. The cytotoxic potential of the random-sequence peptide mixtures was determined following incubation of exponentially growing cells using the MTT assay. As shown in FIG. 9, random-sequence peptide mixtures (.sup.LF.sup.LK or .sup.LF.sup.DK) exhibited less cytotoxicity compared to leucine-lysine mixture at 200 and 400 μg/ml concentrations.

[0140] The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without undue experimentation and without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. The means, materials, and steps for carrying out various disclosed functions may take a variety of alternative forms without departing from the invention.